Trio of Committee Proceedings on Drug Pricing Offer Chance to Focus on Areas of Bipartisan Consensus
For Immediate Release
Contact: Jon Conradi
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday ahead of three legislative proceedings on drug pricing proposals scheduled for Thursday. The U.S. House Committee on Ways and Means is slated to hold a hearing titled “Investing in the U.S. Health System by Lowering Drug Prices, Reducing Out-of-Pocket Costs, And Improving Medicare Benefits.” The House Committee on Energy and Commerce and Committee on Education and Labor are scheduled to hold legislative markups of The Lower Drug Costs Now Act of 2019 (H.R. 3).
“Now is a critical time for lawmakers to maintain the bipartisan momentum to hold Big Pharma accountable and lower prescription drug prices,” said CSRxP executive director Lauren Aronson. “There is already broad bipartisan consensus on a number of important measures, including Medicare Part D reform that holds Big Pharma accountable for the industry’s price-gouging, caps out-of-pocket costs for seniors and keeps drug price increases below the rate of inflation.”
“With political pressures mounting and an election year approaching, lawmakers should focus on areas of consensus and work across party lines to swiftly advance solutions to hold Big Pharma accountable and lower drug prices,” Aronson added.
See a CSRxP infographic detailing measures with significant bipartisan consensus in Congress HERE.
Read more on CSRxP’s take on the drug pricing package put forward by Speaker Pelosi HERE.
Read more on CSRxP’s take on the Senate Finance drug pricing package HERE.
Read more on additional market-based solutions to hold Big Pharma accountable and lower drug pricesHERE.